Unity Biotechnology - UBX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 305.41%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.48
▲ +0.02 (1.37%)

This chart shows the closing price for UBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Unity Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UBX

Analyst Price Target is $6.00
▲ +305.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. The average price target is $6.00, with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 305.41% upside from the last price of $1.48.

This chart shows the closing price for UBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Unity Biotechnology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
4/16/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $8.00Low
11/16/2023WedbushUpgradeNeutral ➝ Outperform$4.00Low
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
6/26/2023WedbushDowngradeOutperform ➝ NeutralLow
5/26/2023CitigroupBoost Target$5.00 ➝ $6.00Low
3/28/2023HC WainwrightReiterated RatingBuy$10.00Low
3/28/2023WedbushLower TargetOutperform$35.00 ➝ $5.00Low
3/28/2023MizuhoLower TargetBuy$12.00 ➝ $6.00Low
3/28/2023CitigroupLower TargetBuy$15.00 ➝ $5.00Low
3/16/2023HC WainwrightReiterated RatingBuy$10.00Low
3/16/2023WedbushReiterated RatingOutperform$35.00Low
2/15/2023HC WainwrightReiterated RatingBuy$10.00Low
11/16/2022MizuhoLower TargetBuy$80.00 ➝ $12.00Low
11/9/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00Low
11/2/2022WedbushBoost TargetOutperform$36.00Low
8/16/2022MizuhoBoost TargetBuy$70.00 ➝ $80.00Low
8/15/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/15/2022CitigroupBoost TargetBuy$50.00 ➝ $80.00Low
5/17/2022CitigroupLower TargetNA$60.00 ➝ $50.00N/A
1/4/2022Roth CapitalUpgradeNeutral ➝ Buy$40.00Low
12/15/2021WedbushReiterated RatingOutperform$40.00High
11/9/2021MizuhoUpgradeNeutral ➝ Buy$50.00 ➝ $70.00High
10/6/2021HC WainwrightReiterated RatingBuy$120.00Medium
7/28/2021HC WainwrightReiterated RatingBuy$120.00High
6/28/2021CitigroupUpgradeSell ➝ BuyHigh
6/7/2021HC WainwrightInitiated CoverageBuy$120.00Low
3/26/2021MizuhoBoost TargetNeutral$40.00 ➝ $50.00High
2/16/2021CitigroupDowngradeNeutral ➝ Sell$50.00 ➝ $60.00Low
8/24/2020MizuhoReiterated RatingBuyHigh
8/18/2020The Goldman Sachs GroupLower TargetNeutral$80.00 ➝ $40.00High
8/18/2020CitigroupDowngradeBuy ➝ Neutral$310.00 ➝ $50.00High
8/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$130.00 ➝ $50.00High
8/17/2020MizuhoDowngradeBuy ➝ Neutral$330.00 ➝ $40.00High
8/17/2020Roth CapitalDowngradeBuy ➝ Neutral$350.00 ➝ $40.00High
7/27/2020Roth CapitalInitiated CoverageBuy$350.00High
4/15/2020Morgan StanleyLower TargetOverweight$140.00 ➝ $130.00Low
12/12/2019Cantor FitzgeraldReiterated RatingOverweight$200.00High
11/18/2019MizuhoReiterated RatingBuy$330.00Medium
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
7/15/2019Morgan StanleySet TargetBuy$140.00Medium
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Unity Biotechnology logo
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.48
Low: $1.45
High: $1.51

50 Day Range

MA: $1.54
Low: $1.42
High: $1.66

52 Week Range

Now: $1.48
Low: $1.42
High: $3.82

Volume

53,589 shs

Average Volume

49,787 shs

Market Capitalization

$24.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Unity Biotechnology?

The following Wall Street analysts have issued stock ratings on Unity Biotechnology in the last twelve months: Citigroup Inc., HC Wainwright, and Wedbush.
View the latest analyst ratings for UBX.

What is the current price target for Unity Biotechnology?

3 Wall Street analysts have set twelve-month price targets for Unity Biotechnology in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 305.4%. HC Wainwright has the highest price target set, predicting UBX will reach $8.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $4.00 for Unity Biotechnology in the next year.
View the latest price targets for UBX.

What is the current consensus analyst rating for Unity Biotechnology?

Unity Biotechnology currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UBX will outperform the market and that investors should add to their positions of Unity Biotechnology.
View the latest ratings for UBX.

What other companies compete with Unity Biotechnology?

How do I contact Unity Biotechnology's investor relations team?

The company's listed phone number is (650) 416-1192 and its investor relations email address is [email protected]. The official website for Unity Biotechnology is www.unitybiotechnology.com. Learn More about contacing Unity Biotechnology investor relations.